Lilly Pushes Buying Spree Beyond $32B With Calytrix Deal
Eli Lilly & Co. agreed to buy closely held Calytrix Bio Inc. in a deal that could be worth up to $1.5 billion, the latest in the drugmaker’s $32 billion wave of acquisitions in 2026.
This latest acquisition is part of Lilly’s broader strategy to build out its cancer and immunology businesses. The company has been on a significant acquisition spree throughout 2026, with a total value of $32 billion.
Sam Fazeli, Bloomberg Intelligence, Director of Research for Global Industries and Senior Pharmaceuticals Analyst, discusses the biotech sector, how AI is playing a role in new developments and the importance of M&A through deals like that of Eli Lilly and Calytrix Bio.
The deal underscores the continued importance of mergers and acquisitions in the biotech sector. Sam Fazeli, Director of Research for Global Industries and Senior Pharmaceuticals Analyst at Bloomberg Intelligence, discussed the sector's dynamics.
